

Supplementary Materials for

Gut resistome of preschool children after prolonged mass azithromycin distribution: a cluster-randomized trial.

Ahmed M. Arzika¹, Ramatou Maliki¹, Amza Abdou^{2,3}, Alio K. Mankara¹, Abdoul N. Harouna¹, Catherine Cook⁴, Armin Hinterwirth⁴, Lee Worden⁴, Lina Zhong⁴, Cindi Chen⁴, Kevin Ruder⁴, Zhaoxia Zhou⁴, Elodie Lebas⁴, Kieran S. O'Brien⁴, Catherine E. Oldenburg^{4,5,6}, Victoria Le⁴, Benjamin Arnold⁴, Travis Porco^{4,5,6}, Jeremy D. Keenan^{4,5,6}, Thomas M. Lietman^{4,5,6,7}, Thuy Doan^{4,5}

This PDF file includes:

Figures S1-S3

Tables S1

Figure S1. Trial Profile




Figure S2: Normalized macrolide resistance determinants for placebo- and azithromycin-treated villages at baseline, 24, 36, 48, and 60 months. Bars indicate the mean and 95% confidence intervals. Each point represents a village.




Figure S3: Normalized non-macrolide resistance determinants for placebo- and azithromycin-treated villages at 60 months. Bars indicate the mean and 95% confidence intervals. Each point represents a village.




Table S1: Demographics of Analyzed Participants

	<i>Rectal Swabs</i> <i>60 months</i>	
	Placebo	Azithromycin
Number of children	557	447
Number of communities	15	14
Mean age, months (95% CI)	32 (31 to 33)	32 (30 to 34)
Female, % (95% CI)	48 (44 to 52)	45 (39 to 50)